• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Invitae Appoints William H. Osborne to its Board of Directors

    1/30/23 7:30:00 AM ET
    $NVTA
    Medical Specialities
    Health Care
    Get the next $NVTA alert in real time by email

    – Brings invaluable expertise in leading, operating and scaling global businesses throughout his career in aerospace, transportation and integrated solutions –

    SAN FRANCISCO, Jan. 30, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, has announced that aerospace, transportation and industrial supplies veteran William H. Osborne has been appointed to its board of directors and will also serve on its audit committee, effective January 26, 2023. 

    www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

    "We are pleased to welcome William (Bill) Osborne to our board of directors and look forward to working with him and taking full advantage of his considerable track record of both operational and governance leadership. Bill has guided multiple companies to achieve transformational growth, scale and innovation, globally," said Ken Knight, president and chief executive officer of Invitae. "Bill's experience in the CEO role and his tenure at both Boeing Company and Navistar demonstrate a breadth and depth of leadership within global enterprises. While at Boeing, Bill served in several senior management positions, led its manufacturing council and provided oversight of corporate environmental health and safety. These roles will offer insight into how companies like ours, in highly competitive industries, can innovate to expand and enhance our service to our patients and customers and streamline processes while fulfilling broader responsibilities to employees and the environment. His perspective and experience from outside the genetics industry will be a valuable addition to our board as we scale our business and bring genetic information into mainstream medicine."

    Mr. Osborne recently retired as senior vice president of operations and total quality for Boeing Defense, Space & Security (BDS), one of The Boeing Company's three business units. The Boeing Company is the world's largest aerospace company and a leading manufacturer of commercial jetliners and defense, space and security systems. He also maintained oversight for environment, health & safety at BDS, was named to lead Boeing's manufacturing council and served on the Boeing executive council. 

    Before joining Boeing, he was senior vice president of global manufacturing and quality at Navistar International Corporation, a holding company whose subsidiaries and affiliates produce International® brand commercial and military trucks. Before joining Navistar, he was president and chief executive officer of Federal Signal Corporation, a designer and manufacturer of a suite of products and integrated solutions for municipal, governmental, industrial and airport customers, from 2008 to 2010.

    "Invitae's focus on making medical genetics affordable, accessible and ubiquitous has the potential to fundamentally transform healthcare. The company is leading the creation of a new industry, creating a network of patients and their data that may support faster diagnoses, better treatments and eventually the eradication of disease," said Osborne. "I'm delighted and grateful for the opportunity to serve the board and the company at this exciting time and look forward to helping the team deliver on its mission to help improve healthcare for billions of people."

    Mr. Osborne currently serves on the board of directors at Quaker Houghton, a global industrial products company where he serves on the compensation, human resources and sustainability committees; as well as at Armstrong World Industries, a leader in the design, innovation and manufacture of ceiling and wall system solutions in America, where he serves on the compensation and governance committees. 

    About Invitae

    Invitae (NYSE:NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.

    To learn more, visit invitae.com and follow for updates on Twitter, Instagram, Facebook and LinkedIn @Invitae.

    Safe Harbor Statement

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's belief that Mr. Osborne's perspective and experience will have a positive impact on the company and its customers; that the company's mission has the potential to transform healthcare; and that the company is leading the creation of a new industry and creating a network of patients and their data that may support better health outcomes. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

    Invitae PR contact: 

    Amy Hadsock

    [email protected] 

    (628) 213-3283

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-appoints-william-h-osborne-to-its-board-of-directors-301732813.html

    SOURCE Invitae Corporation

    Get the next $NVTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVTA

    DatePrice TargetRatingAnalyst
    7/5/2023Underweight
    JP Morgan
    5/15/2023Mkt Perform → Underperform
    Raymond James
    1/31/2023$2.00Neutral → Sell
    Goldman
    8/25/2022$1.00Underperform
    Credit Suisse
    8/10/2022Neutral → Underweight
    JP Morgan
    7/26/2022$8.00 → $2.50Outperform → Market Perform
    Cowen
    7/21/2022Outperform → Mkt Perform
    Raymond James
    7/20/2022Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $NVTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Announces Winning Bid for Select Assets of Invitae

      Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.

      4/24/24 9:27:00 PM ET
      $LH
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Enters into Agreement with Labcorp for Sale of Business

      – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis

      4/24/24 9:19:00 PM ET
      $LH
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Publishes its Environmental, Social and Governance (ESG) Report

      – Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring c

      4/22/24 12:43:00 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nussbaum Robert L covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 3% to 551,941 units (SEC Form 4)

      4 - Invitae Corp (0001501134) (Issuer)

      12/21/23 9:20:16 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Brida Thomas covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 2% to 916,183 units (SEC Form 4)

      4 - Invitae Corp (0001501134) (Issuer)

      12/21/23 9:14:33 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Sholehvar David was granted 850,000 shares (SEC Form 4)

      4 - Invitae Corp (0001501134) (Issuer)

      11/14/23 7:58:49 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

      SC 13G/A - Invitae Corp (0001501134) (Subject)

      2/13/24 5:07:58 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

      SC 13G/A - Invitae Corp (0001501134) (Subject)

      2/13/24 9:10:56 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

      SC 13G/A - Invitae Corp (0001501134) (Subject)

      2/5/24 6:08:57 AM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Invitae Corporation

      25-NSE - Invitae Corp (0001501134) (Subject)

      2/21/24 8:59:54 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Invitae Corp (0001501134) (Filer)

      2/14/24 6:59:56 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Invitae Corp (0001501134) (Filer)

      2/6/24 5:07:32 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Invitae

      JP Morgan resumed coverage of Invitae with a rating of Underweight

      7/5/23 7:28:43 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae downgraded by Raymond James

      Raymond James downgraded Invitae from Mkt Perform to Underperform

      5/15/23 7:28:13 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae downgraded by Goldman with a new price target

      Goldman downgraded Invitae from Neutral to Sell and set a new price target of $2.00

      1/31/23 6:15:23 AM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Leadership Updates

    Live Leadership Updates

    See more

    $NVTA
    Financials

    Live finance-specific insights

    See more
    • Aranscia Acquires YouScript from Invitae

      Pioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs. YouSc

      11/15/23 4:35:00 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

      SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition.  www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the qu

      9/25/23 4:30:00 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer

      – Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth –  SAN FRANCISCO, Aug. 28, 2023  /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He will develop and implement Invitae's commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of

      8/28/23 4:02:00 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Natera Acquires Reproductive Health Assets from Invitae

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE:NVTA), a leading medical genetics company, certain assets relating to Invitae's non-invasive prenatal screening and carrier screening business. Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the transaction includes $42.5 million in potential milestone payments including cash and litigation-related credits. Pursuant to the agreement, Invitae will transition its non-invasive prenatal screening and carrier screening customers to Natera. "We are committed to providing excellent service, and we look forward to the o

      1/22/24 7:00:00 AM ET
      $NTRA
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Reports Second Quarter 2023 Financial Results

      – Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year –  – GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters – – Company improves ongoing cash burn annual guidance to $220-$245 million; adjusts 2023 revenue guidance to $480-$500 million from over $500 million previously – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, Aug. 8, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating res

      8/8/23 4:01:00 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

      SAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

      7/26/23 4:01:00 PM ET
      $NVTA
      Medical Specialities
      Health Care